Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer

Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and epidermal growth factor receptor (EGFR) family signaling are drivers of tumorigenesis in pancreatic ductal adenocarcinoma (PDAC). Previous studies have demonstrated that combinatorial treatment of PDAC xenografts with the mitogen-activa...

Full description

Bibliographic Details
Main Authors: James M. Lindberg, Timothy E. Newhook, Sara J. Adair, Dustin M. Walters, Alison J. Kim, Edward B. Stelow, J. Thomas Parsons, Todd W. Bauer
Format: Article
Language:English
Published: Elsevier 2014-07-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558614000785

Internet

http://www.sciencedirect.com/science/article/pii/S1476558614000785

Similar Items